Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review

Marek Mazurek, Małgorzata Szlendak, Alicja Forma, Jacek Baj, Ryszard Maciejewski, Giandomenico Roviello, Luigi Marano, Franco Roviello, Karol Polom and Robert Sitarz
Additional contact information
Marek Mazurek: Department of Surgical Oncology, Voivodship Hospital in Siedlce, 08-110 Siedlce, Poland
Małgorzata Szlendak: Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland
Alicja Forma: Department of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland
Jacek Baj: Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland
Ryszard Maciejewski: Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland
Giandomenico Roviello: Department of Health Sciences, University of Florence, 50139 Florence, Italy
Luigi Marano: Department of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy
Franco Roviello: Department of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy
Karol Polom: Department of Surgical Oncology, Medical University of Gdansk, 80-070 Gdansk, Poland
Robert Sitarz: Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland

IJERPH, 2022, vol. 19, issue 2, 1-19

Abstract: Gastric cancer (GC) patients with peritoneal metastasis tend to achieve poor clinical outcomes. Until recently, the treatment options were limited mainly to either palliative chemotherapy or radiation therapy in exceptional cases. Currently, these patients benefit from multimodal treatment, such as cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Despite good overall results, this treatment modality is still widely debated. The following study is designed to assess the papers about the possible application and utility of HIPEC in GC. A search in the PubMed, Web of Science, and Scopus databases was performed to assess the papers devoted to the role of HIPEC in GC treatment; a literature search was performed until March 21st; and, finally, 50 studies with a total number of 3946 patients were analyzed. According to the most recent data, it seems to be reasonable to limit the duration of HIPEC to the shortest effective time. Moreover, the drugs used in HIPEC need to have equal concentrations and the same solvent. Perioperative chemotherapy needs to be reported in detail and, furthermore, the term “morbidity” should be defined more clearly by the authors.

Keywords: gastric cancer; hyperthermic intraperitoneal chemotherapy; peritoneal metastasis; cytoreductive surgery; cancer treatment (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/2/681/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/2/681/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:2:p:681-:d:720050

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().